Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging
Autore:
Reggiani, A; Pietra, C; Arban, R; Marzola, P; Guerrini, U; Ziviani, L; Boicelli, A; Sbarbati, A; Osculati, F;
Indirizzi:
Univ Verona, Fac Med, Inst Anat & Histol, I-37134 Verona, Italy Univ Verona Verona Italy I-37134 st Anat & Histol, I-37134 Verona, Italy Glaxo Wellcome SpA, Res Labs, Verona, Italy Glaxo Wellcome SpA Verona Italy o Wellcome SpA, Res Labs, Verona, Italy Hosp San Raffaele, IRCCS, I-20132 Milan, Italy Hosp San Raffaele Milan Italy I-20132 faele, IRCCS, I-20132 Milan, Italy
Titolo Testata:
EUROPEAN JOURNAL OF PHARMACOLOGY
fascicolo: 2-3, volume: 419, anno: 2001,
pagine: 147 - 153
SICI:
0014-2999(20010511)419:2-3<147:TNAOTG>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
FOCAL CEREBRAL-ISCHEMIA; ATTENUATES INFARCT SIZE; D-ASPARTATE ANTAGONIST; GLUTAMATE ANTAGONIST; EXPERIMENTAL STROKE; ARTERY OCCLUSION; NMDA ANTAGONIST; RAT-BRAIN; DIFFUSION; MK-801;
Keywords:
stroke; MRI (magnetic resonance imaging); (rat); GV150526; focal ischemia; neurodegeneration;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Sbarbati, A Univ Verona, Fac Med, Inst Anat & Histol, Strada Le Grazie 8, I-37134 Verona, Italy Univ Verona Strada Le Grazie 8 Verona Italy I-37134 na, Italy
Citazione:
A. Reggiani et al., "The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging", EUR J PHARM, 419(2-3), 2001, pp. 147-153

Abstract

The neuroprotective activity of GV150526 (3-[2-(Phenylaminocarbonyl)ethenyl]-4,6-dichloroindole-2-carboxylic acid sodium salt), a selective glycine receptor antagonist of the NMDA receptor, has been evaluated by magnetic resonance imaging (MRI) in a rat model of middle cerebral artery occlusion. The aim of the work was to evaluate, using an in vivo method, whether GV150526 was able to reduce the extent of ischemic brain damage when administered both before and after (6 h) middle cerebral artery occlusion. GV150526 was administered at a dose of 3 mg/kg i.v. T2-weighted (T2W) and diffusion weighted (DW) images were acquired at 6, 24 and 144 h after the establishment of the cerebral ischemia. Substantial neuroprotection was demonstrated at all investigated time points when GV150526 was administered before the ischemic insult. The ischemic volume was reduced by 84% and 72%, compared to control values, when measured from T2W and DW images, acquired 24 h after middle cerebral artery occlusion. Administration of the same dose of GV150526, 6h post-ischemia, also resulted in a significant (p < 0.05) neuroprotection. The ischemic volume was reduced by 48% from control values when measured from T2W images and by 45% when measured! from DW images. No significant difference was found between volumes of brain ischemia obtained by either MRIor triphenyltetrazolium chloride staining. These data confirm the potential neuroprotective activity of the glycine receptor antagonist GV150526 whenadministered either before or up to 6 h after ischemia. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 14:41:26